This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!
EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stock Under $10 that he thinks could potentially double or triple in the next 6 to 12-months. See what he's trading today with a 14-day FREE pass.

Insider Trading Alert - Aqua America And 3 Others Traded By Insiders

Covidien (COV) - FREE Research Report

Almeida Jose E who is President and Chief Executive at COVIDIEN sold 979 shares at $57.41 per share for a total value of $56,204.39 on July 1, 2013. Following this transaction, the President and Chief Executive owned 212,478 shares meaning that the stake was reduced by 0.46% with the 979 share sell-off.

Hanson Bryan C who is Senior Vice President at COVIDIEN sold 224 shares at $57.41 per share for a total value of $12,859.84 on July 1, 2013. Following this transaction, the Senior Vice President owned 21,741 shares meaning that the stake was reduced by 1.02% with the 224 share sell-off.

Sgrignari Michael who is Senior Vice President at COVIDIEN sold 53 shares at $57.41 per share for a total value of $3,042.73 on July 1, 2013. Following this transaction, the Senior Vice President owned 22,096 shares meaning that the stake was reduced by 0.24% with the 53 share sell-off.

Wehrly Peter L who is Senior Vice President at COVIDIEN sold 273 shares at $57.41 per share for a total value of $15,672.93 on July 1, 2013. Following this transaction, the Senior Vice President owned 24,985 shares meaning that the stake was reduced by 1.08% with the 273 share sell-off.

The shares most recently traded at $57.76, up $0.64, or 1.12% since the insider transactions. Historical insider transactions for Covidien go as follows:

  • 4-Week # shares sold: 2,652
  • 12-Week # shares sold: 19,180
  • 24-Week # shares sold: 29,180

The average volume for Covidien has been 3.3 million shares per day over the past 30 days. Covidien has a market cap of $27.0 billion and is part of the health care sector and health services industry. Shares are down 0.57% year to date as of the close of trading on Tuesday.

Covidien plc develops, manufactures, and sells healthcare products for use in clinical and home settings worldwide. The stock currently has a dividend yield of 1.81%. The company has a P/E ratio of 14.9. Currently there are 14 analysts that rate Covidien a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on COV - FREE

TheStreet Quant Ratings rates Covidien as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, reasonable valuation levels, good cash flow from operations, increase in stock price during the past year and expanding profit margins. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Covidien Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

3 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
Submit an article to us!

Markets

DOW 18,030.21 +6.04 0.03%
S&P 500 2,081.88 -0.29 -0.01%
NASDAQ 4,773.4720 +8.0480 0.17%

Brokerage Partners

Top Rated Stocks Top Rated Funds Top Rated ETFs